Home > Insider Trading > Filing (0000899243-16-015628)

Filing Details

Accession Number:: 0000899243-16-015628
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-03-09 16:30:44
Reporting Period:: 2016-03-07

Filing Date:: 2016-03-09
Accepted Time:: 2016-03-09 16:30:44
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1369868	China Biologic Products Inc.	CBPO	()	NY

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
929408	Warburg Pincus & Co.	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	Yes	No	Yes	No
1162870	Warburg Pincus Llc	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No
1414561	Warburg Pincus X, L.p.	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	Yes	No	Yes	No
1414564	L.p. Gp X Pincus Warburg	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	Yes	No	Yes	No
1414565	Warburg Pincus Private Equity X, L.p.	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	Yes	No	Yes	No
1451560	Warburg Pincus X Partners, L.p.	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	Yes	No	No	No
1575882	Wp X Biologics Llc	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	Yes	No	Yes	No
1621224	Warburg Pincus Partners Gp Llc	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	Yes	No	Yes	No
1621242	Warburg Pincus Partners, L.p.	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	Yes	No	Yes	No
1621874	Wpp Gp Llc	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2016-03-07	4,257,000	$107.00	4,087,200	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Footnotes

The shares of common stock, $0.0001 par value per share (the "Common Stock") reported in Column 4 of this Form 4 were sold pursuant to that certain amended and restated underwriting agreement dated March 2, 2016 (the "Underwriting Agreement"), entered into by and among China Biologic Products, Inc. (the "Issuer"), Warburg Pincus Private Equity X, L.P., a Delaware limited partnership ("WP X"), Warburg Pincus X Partners, L.P., a Delaware limited partnership ("WPP X," together with WP X, the "Funds") and Morgan Stanley & Co. International plc, as the underwriter named in the Underwriting Agreement (the "Underwriter"). At the closing of the transaction contemplated under the Underwriting Agreement, on March 7, 2016, the Funds sold an aggregate of 4,257,000 shares of Common Stock to the Underwriter for a purchase price of $455,499,000.00, or $107.00 per share.
As of March 7, 2016, WP X Biologics LLC, a Delaware limited liability company ("WP X B"), is the holder of an aggregate of 3,112,920 shares of Common Stock of the Issuer. WP X B is owned 96.9% by WP X and 3.1% by WPP X, and therefore, WP X may be deemed to beneficially own 3,960,496 shares of Common Stock, including 944,077 shares that it directly holds, and WPP X may be deemed to beneficially own 126,704 shares of Common Stock, including 30,203 shares that it directly holds. By reason of the provisions of Rule 16a-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), Warburg Pincus X, L.P., a Delaware limited partnership ("WP X LP") and the general partner of each of the Funds, Warburg Pincus X GP L.P., a Delaware limited partnership ("WP X GP"), and the general partner of WP X LP, WPP GP LLC, a Delaware limited liability company ("WPP GP"), and the general partner of WP X GP,
(Continued from footnote 2) Warburg Pincus Partners, L.P., a Delaware limited partnership ("WP Partners"), and the managing member of WPP GP, Warburg Pincus Partners GP LLC, a Delaware limited liability company ("WPP GP LLC"), and the general partner of WP Partners, Warburg Pincus & Co., a New York limited liability company ("WP"), and the managing member of WPP GP LLC, Warburg Pincus LLC, a New York limited liability company ("WP LLC"), that manages each of the Funds, and Messrs. Charles R. Kaye and Joseph P. Landy, each a Managing General Partner of WP and a Co-Chief Executive Officer and Managing Member of WP LLC (each of the foregoing, a "Warburg Pincus Reporting Person" and collectively, the "Warburg Pincus Reporting Persons") may be deemed to be the beneficial owner of the shares of Common Stock of the Issuer held by the Funds and WP X B. Messrs. Kaye and Landy may be deemed to control WP X B, the Funds, WP X LP, WP X GP, WPP GP, WP Partners, WPP GP LLC, WP and WP LLC.
Information with respect to each of the Warburg Pincus Reporting Persons is given solely by such Warburg Pincus Reporting Person, and no Warburg Pincus Reporting Person has responsibility for the accuracy or completeness of information supplied by another Warburg Pincus Reporting Person.
Pursuant to Rule 16a-1(a)(4) of the Exchange Act, each of the Warburg Pincus Reporting Persons, other than WP X B and the Funds, herein states that this Form 4 shall not be deemed an admission that it or he is the beneficial owner of any of the shares of Common Stock of the Issuer reported in this Form 4. Each of WP X LP, WP X GP, WPP GP, WP Partners, WPP GP LLC, WP, WP LLC, and Messrs. Kaye and Landy disclaims beneficial ownership of the Common Stock of the Issuer, except to the extent of its or his pecuniary interest in such shares of Common Stock.